Stocks
Blueprint Medicines Corporation Financial Statements (BPMC) |
||||||||||
| Blueprint Medicines Corporationsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 13.02.2020 | 17.02.2021 | 17.02.2022 | 16.02.2023 | 15.02.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 66.5 | 793.7 | 180.1 | 204.0 | 249.4 | 434.4 | |||
| Operating Income, bln rub | -366.6 | 302.1 | -648.5 | -549.3 | -486.3 | -276.0 | ||||
| EBITDA, bln rub | ? | -356.1 | 308.7 | -628.3 | -515.4 | -474.6 | -240.4 | |||
| Net profit, bln rub | ? | -328.7 | 313.9 | -644.1 | -557.5 | -507.0 | -128.1 | |||
| OCF, bln rub | ? | -278.0 | 387.0 | -298.7 | -502.3 | -436.8 | -242.2 | |||
| CAPEX, bln rub | ? | 14.0 | 3.16 | 261.2 | 8.92 | 16.1 | 8.37 | |||
| FCF, bln rub | ? | -292.0 | 383.9 | -559.9 | -511.2 | -452.9 | -250.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 427.8 | 484.6 | 804.1 | 723.7 | 722.9 | 687.4 | ||||
| Cost of production, bln rub | 0.000 | 0.425 | 17.9 | 17.8 | 12.8 | 22.9 | ||||
| R&D, bln rub | 331.5 | 326.9 | 601.0 | 477.4 | 427.7 | 345.3 | ||||
| Interest expenses, bln rub | 13.7 | 0.000 | 0.000 | 16.8 | 0.000 | 65.6 | ||||
| Assets, bln rub | 707.7 | 1 718 | 1 252 | 1 350 | 1 049 | 1 200 | ||||
| Net Assets, bln rub | ? | 464.4 | 1 470 | 970.7 | 514.7 | 130.6 | 313.1 | |||
| Debt, bln rub | 95.9 | 89.6 | 111.4 | 242.5 | 774.1 | 471.5 | ||||
| Cash, bln rub | 548.0 | 1 550 | 1 035 | 1 078 | 710.6 | 734.2 | ||||
| Net debt, bln rub | -452.0 | -1 460 | -923.2 | -836.0 | 63.5 | -262.7 | ||||
| Ordinary share price, rub | 80.1 | 112.2 | 107.1 | 43.8 | 92.2 | 59.5 | ||||
| Number of ordinary shares, mln | 47.8 | 54.5 | 58.5 | 59.6 | 60.6 | 63.4 | ||||
| Market cap, bln rub | 3 832 | 6 116 | 6 268 | 2 613 | 5 586 | 3 769 | ||||
| EV, bln rub | ? | 3 380 | 4 656 | 5 345 | 1 777 | 5 649 | 3 506 | |||
| Book value, bln rub | 464 | 1 470 | 971 | 515 | 131 | 313 | ||||
| EPS, rub | ? | -6.87 | 5.76 | -11.0 | -9.35 | -8.37 | -2.02 | |||
| FCF/share, rub | -6.11 | 7.04 | -9.57 | -8.57 | -7.48 | -3.95 | ||||
| BV/share, rub | 9.71 | 27.0 | 16.6 | 8.63 | 2.16 | 4.94 | ||||
| EBITDA margin, % | ? | -535.3% | 38.9% | -348.9% | -252.6% | -190.3% | -55.3% | |||
| Net margin, % | ? | -494.2% | 39.5% | -357.7% | -273.2% | -203.3% | -29.5% | |||
| FCF yield, % | ? | -7.62% | 6.28% | -8.93% | -19.6% | -8.11% | -6.65% | |||
| ROE, % | ? | -70.8% | 21.4% | -66.4% | -108.3% | -388.2% | -40.9% | |||
| ROA, % | ? | -46.4% | 18.3% | -51.4% | -41.3% | -48.3% | -10.7% | |||
| P/E | ? | -11.7 | 19.5 | -9.73 | -4.69 | -11.0 | -29.4 | |||
| P/FCF | -13.1 | 15.9 | -11.2 | -5.11 | -12.3 | -15.0 | ||||
| P/S | ? | 57.6 | 7.71 | 34.8 | 12.8 | 22.4 | 8.68 | |||
| P/BV | ? | 8.25 | 4.16 | 6.46 | 5.08 | 42.8 | 12.0 | |||
| EV/EBITDA | ? | -9.49 | 15.1 | -8.51 | -3.45 | -11.9 | -14.6 | |||
| Debt/EBITDA | 1.27 | -4.73 | 1.47 | 1.62 | -0.13 | 1.09 | ||||
| R&D/CAPEX, % | 2 365% | 10 347% | 230.1% | 5 353% | 2 663% | 4 125% | ||||
| CAPEX/Revenue, % | 21.1% | 0.40% | 145.1% | 4.37% | 6.44% | 1.93% | ||||
| Blueprint Medicines Corporation shareholders | ||||||||||
